Patents by Inventor Aloysius O. Anaebonam
Aloysius O. Anaebonam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6254891Abstract: An extended release acetaminophen composition comprises particles containing acetaminophen coated on sugar/starch seeds. The particles are present as a blend of both an immediate release and a controlled release form. The composition, when contained within a gelatin capsule and assayed in a USP Apparatus I rotating basket at 50 rpm in 900 mL of phosphate buffer at pH 5.8 and a temperature of 37° C., exhibits about 40 percent acetaminophen dissolution at one-half hour, about 55 percent acetaminophen dissolution at one hour, and substantially complete dissolution of acetaminophen at six hours. A process for treating a human patient with the extended release acetaminophen composition is also disclosed.Type: GrantFiled: September 3, 1998Date of Patent: July 3, 2001Assignee: Ascent Pediatrics, Inc.Inventors: Aloysius O. Anaebonam, Emmett Clemente, Robert W. Mendes
-
Patent number: 6126967Abstract: An extended release acetaminophen composition comprises a plurality of discrete particles containing acetaminophen which, when contained within a gelatin capsule and assayed in a USP Apparatus I rotating basket at 50 rpm in 900 mL of phosphate buffer at pH 5.8 and 37.degree. C., exhibits about 40 percent to about 53 percent acetaminophen dissolution at one-half hour, about 50 percent to about 68 percent dissolution at 45 minutes, about 57 percent to about 77 percent acetaminophen dissolution at one hour, and about 82 percent to about 92 percent acetaminophen dissolution at two hours. After six hours, the contemplated extended release acetaminophen composition exhibits substantially complete dissolution. A process for treating a human patient with the extended release acetaminophen composition is also disclosed.Type: GrantFiled: September 3, 1998Date of Patent: October 3, 2000Assignee: Ascent PediatricsInventors: Emmett Clemente, Aloysius O. Anaebonam, Robert W. Mendes, Abdel A. Fawzy, Eric M. Morrel
-
Patent number: 5962461Abstract: A liquid pharmaceutical composition is contemplated that comprises a pharmaceutically effective amount of a bitter tasting drug dissolved or dispersed in an aqueous medium that is free of ethanol. That aqueous medium consists essentially of water, about 5 to about 30 weight percent polyvinylpyrrolidone, about 35 to about 55 weight percent of a C.sub.3 -C.sub.6 polyol, about 0.01 to about 0.5 weight percent ammonium glycyrrhizinate and one or more flavorants. The liquid composition is transparent and has a pleasant taste. The bitter tasting drugs claimed herein are vitamin and mineral preparations, trimethoprim, and guaifenesin.Type: GrantFiled: June 18, 1998Date of Patent: October 5, 1999Assignee: Ascent Pediatrics, Inc.Inventors: Aloysius O. Anaebonam, Emmett Clemente, Abdel A. Fawzy
-
Patent number: 5763449Abstract: A liquid pharmaceutical composition is contemplated that comprises a pharmaceutically effective amount of a bitter tasting drug dissolved or dispersed in an aqueous medium that is free of ethanol. That aqueous medium consists essentially of water, about 5 to about 30 weight percent polyvinylpyrrolidone, about 45 to about 55 weight percent of a C.sub.3 -C.sub.6 polyol, about 0.01 to about 0.5 weight percent ammonium glycyrrhizinate and one or more flavorants. The liquid composition is transparent and has a pleasant taste.Type: GrantFiled: August 7, 1996Date of Patent: June 9, 1998Assignee: Ascent Pediatrics, Inc.Inventors: Aloysius O. Anaebonam, Emmett Clemente, Abdel A. Fawzy
-
Patent number: 5684038Abstract: A process and pharmaceutical composition for the prevention and treatment of cutaneous Type I hypersensitivity reactions in humans is disclosed. The pharmaceutical composition comprises of a chromone compound of the following formula, or a pharmacologically acceptable salt, ester or amide thereof: ##STR1## dissolved or dispersed in a pharmacologically acceptable carrier. In accordance with the process, a preventively or therapeutically effective amount of the composition is topically administered to a human patient, as required; i.e. for prevention the composition is administered to the area of skin susceptible to exposure to antigen and for treatment the composition is administered to the reaction site.Type: GrantFiled: June 28, 1996Date of Patent: November 4, 1997Assignee: Ascent Pharmaceuticals, Inc.Inventors: Emmett Clemente, Robert W. Mendes, Aloysius O. Anaebonam, Mumtaz Ahmed
-
Patent number: 5684037Abstract: A process and pharmaceutical composition for the prevention and treatment of cutaneous Type I hypersensitivity reactions in humans is disclosed. The pharmaceutical composition comprises of a chromone compound of the following formula, or a pharmacologically acceptable salt, ester or amide thereof: ##STR1## dissolved or dispersed in a pharmacologically acceptable carrier. In accordance with the process, a preventively or therapeutically effective amount of the composition is topically administered to a human patient, as required; i.e. for prevention the composition is administered to the area of skin susceptible to exposure to antigen and for treatment the composition is administered to the reaction site.Type: GrantFiled: June 28, 1996Date of Patent: November 4, 1997Assignee: Ascent Pharmaceuticals, Inc.Inventors: Emmett Clemente, Robert W. Mendes, Aloysius O. Anaebonam, Mumtaz Ahmed
-
Patent number: 5626879Abstract: The present invention contemplates a dry, granular terfenadine composition. That composition comprises (i) particulate terfenadine and (ii) a polyethylene oxide-polypropylene oxide-polyethylene oxide block copolymer having an HLB number of 24 that is a wetting agent for the terfenadine that are dry-blendedly dispersed onto (iii) spray-dried sorbitol particles that are loosely packed, randomly oriented filamentary crystals having pores that entrap the particulate terfenadine and wetting agent upon the dry-blended dispersal. The weight ratio of particulate terfenadine to the block copoymer is about 1:1 to about 1:5:1, and the weight ratio of terfenadine to the spray-dried sorbitol is about 1:4 to about 1:10. The composition is free-flowing and is substantially free from the taste of solubilized terfenadine when placed on the human tongue in dry form or when dispersed in water and tasted within about five minutes of said dispersal.Type: GrantFiled: October 2, 1995Date of Patent: May 6, 1997Assignee: Ascent Pharmaceuticals, Inc.Inventors: Aloysius O. Anaebonam, Abdel A. Fawzy, Emmett Clemente
-
Patent number: 5576346Abstract: A process and pharmaceutical composition for treatment of uremic pruritus in humans is disclosed. The pharmaceutical composition comprises of a chromone compound of the following formula, or a pharmacologically acceptable salt, ester or amide thereof: ##STR1## dissolved or dispersed in a pharmacologically acceptable carrier. In accordance with the process, a therapeutically effective amount of the composition is topically administered to a pruritic lesion of a human patient.Type: GrantFiled: April 3, 1995Date of Patent: November 19, 1996Assignee: Ascent Pharmaceuticals, Inc.Inventors: Emmett Clemente, Robert W. Mendes, Aloysius O. Anaebonam, Mumtaz Ahmed
-
Patent number: 5552436Abstract: A process and pharmaceutical composition for treatment of hemangioma in humans is disclosed. The pharmaceutical composition comprises a chromone compound of the following formula, or a pharmacologically acceptable salt, ester or amide thereof: ##STR1## dissolved or dispersed in a pharmacologically acceptable carrier. In accordance with the process, a therapeutically effective amount of the composition is topically administered to a hemangioma of a human patient.Type: GrantFiled: April 3, 1995Date of Patent: September 3, 1996Assignee: Ascent Pharmaceuticals, Inc.Inventors: Emmett Clemente, Robert W. Mendes, Aloysius O. Anaebonam, Mumtaz Ahmed
-
Patent number: 5532270Abstract: A process and pharmaceutical composition for the prevention and treatment of cutaneous Type I hypersensitivity reactions in humans is disclosed. The pharmaceutical composition comprises of a chromone compound of the following formula, or a pharmacologically acceptable salt, ester or amide thereof: ##STR1## dissolved or dispersed in a pharmacologically acceptable carrier. In accordance with the process, a preventively or therapeutically effective amount of the composition is topically administered to a human patient, as required; i.e. for prevention the composition is administered to the area of skin susceptible to exposure to antigen and for treatment the composition is administered to the reaction site.Type: GrantFiled: April 3, 1995Date of Patent: July 2, 1996Assignee: Ascent Pharmaceuticals, Inc.Inventors: Emmett Clemente, Robert W. Mendes, Aloysius O. Anaebonam, Mumtaz Ahmed
-
Patent number: 5455049Abstract: The present invention contemplates a dry, powdered terfenadine composition. That composition comprises(a) a mixture of:(i) about 1 to about 20 parts by weight micronized terfenadine and(ii) about 0.Type: GrantFiled: January 4, 1995Date of Patent: October 3, 1995Assignee: Ascent Pharmaceuticals, Inc.Inventors: Aloysius O. Anaebonam, Abdel A. Fawzy, Emmett Clemente